Pfizer's RSV vaccine wins support of FDA panel despite lingering safety and efficacy questions

Though safety signals and study design vexed FDA expert advisors, Pfizer’s vaccine candidate for respiratory syncytial virus (RSV), Abrysvo, ultimately won over the group at a Tuesday meeting.

The question of the day? Whether the safety and efficacy of the shot—known in the clinic as RSVPreF—merits an approval to prevent lower respiratory tract disease caused by RSV in older adults.